Epigenetic silencing of DAPK1 gene is associated with faster disease progression in India populations with chronic myeloid leukemia

Rashid Mir, Imtiyaz Ahmad, Jamsheed Javid, Shazia Farooq, Prasant Yadav, Mariyam Zuberi, M. Masroor, Sameer Guru, Ajaz Ahmad Bhat, Tanveer Ah Khatlani, Naresh Gupta, P. C. Ray, Alpana Saxena

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: One of the major epigenetic changes in human cancer is DNA methylation of tumour suppressor genes which leads to silencing of gene leading to disease progression. Therefore, DNA methylation status of such genes may serve as the epigenetic biomarker for prognosis of human Chronic Myeloid Leukemia. Material and methods: We used MSP-PCR technique for the analysis of aberrant promoter DAPK1 methylation on 200 CML venous blood samples. Stastical analysis was done for evaluating differences between different parameters using SPSS 16.0 version. Results: We could detect 91/200 promoter methylation (45.5%) in CML patients. Percentage of methylation detected was seen higher in blast phase (63.07%) and in accelerated phase (48.1%) than in chronic phase (29.6%). A significant correlation was seen between CML stages and DAPK1 aberrant methylation. We also found a significant association of DAPK1 methylation in gender and in haematological resistance CML patients. However no correlation was found between DAPK1 promoter methylation and other clinical parameters like age, BCR-ABL type and Thrombocytopenia. Conclusion: In summary we concluded that methylation status of DAPK1 gene is associated with advanced phase of CML and may be related to disease progression in chronic myeloid leukemia. Further study on a more number of patients is needed to explore the role of DAPK1 methylation in the prognosis of CML.

Original languageEnglish
Pages (from-to)144-149
Number of pages6
JournalJournal of Cancer Science and Therapy
Volume5
Issue number4
DOIs
Publication statusPublished - 30 May 2013
Externally publishedYes

Fingerprint

Gene Silencing
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Epigenomics
Methylation
Disease Progression
India
Population
DNA Methylation
Blast Crisis
Tumor Suppressor Genes
Thrombocytopenia
Genes
Biomarkers
Polymerase Chain Reaction

Keywords

  • Chronic myeloid leukemia
  • DAPK1 Gene
  • Methylation
  • MSP-PCR technique

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Epigenetic silencing of DAPK1 gene is associated with faster disease progression in India populations with chronic myeloid leukemia. / Mir, Rashid; Ahmad, Imtiyaz; Javid, Jamsheed; Farooq, Shazia; Yadav, Prasant; Zuberi, Mariyam; Masroor, M.; Guru, Sameer; Bhat, Ajaz Ahmad; Ah Khatlani, Tanveer; Gupta, Naresh; Ray, P. C.; Saxena, Alpana.

In: Journal of Cancer Science and Therapy, Vol. 5, No. 4, 30.05.2013, p. 144-149.

Research output: Contribution to journalArticle

Mir, R, Ahmad, I, Javid, J, Farooq, S, Yadav, P, Zuberi, M, Masroor, M, Guru, S, Bhat, AA, Ah Khatlani, T, Gupta, N, Ray, PC & Saxena, A 2013, 'Epigenetic silencing of DAPK1 gene is associated with faster disease progression in India populations with chronic myeloid leukemia', Journal of Cancer Science and Therapy, vol. 5, no. 4, pp. 144-149. https://doi.org/10.4172/1948-5956.1000201
Mir, Rashid ; Ahmad, Imtiyaz ; Javid, Jamsheed ; Farooq, Shazia ; Yadav, Prasant ; Zuberi, Mariyam ; Masroor, M. ; Guru, Sameer ; Bhat, Ajaz Ahmad ; Ah Khatlani, Tanveer ; Gupta, Naresh ; Ray, P. C. ; Saxena, Alpana. / Epigenetic silencing of DAPK1 gene is associated with faster disease progression in India populations with chronic myeloid leukemia. In: Journal of Cancer Science and Therapy. 2013 ; Vol. 5, No. 4. pp. 144-149.
@article{9a739516b0e94339b801772575f63b65,
title = "Epigenetic silencing of DAPK1 gene is associated with faster disease progression in India populations with chronic myeloid leukemia",
abstract = "Background: One of the major epigenetic changes in human cancer is DNA methylation of tumour suppressor genes which leads to silencing of gene leading to disease progression. Therefore, DNA methylation status of such genes may serve as the epigenetic biomarker for prognosis of human Chronic Myeloid Leukemia. Material and methods: We used MSP-PCR technique for the analysis of aberrant promoter DAPK1 methylation on 200 CML venous blood samples. Stastical analysis was done for evaluating differences between different parameters using SPSS 16.0 version. Results: We could detect 91/200 promoter methylation (45.5{\%}) in CML patients. Percentage of methylation detected was seen higher in blast phase (63.07{\%}) and in accelerated phase (48.1{\%}) than in chronic phase (29.6{\%}). A significant correlation was seen between CML stages and DAPK1 aberrant methylation. We also found a significant association of DAPK1 methylation in gender and in haematological resistance CML patients. However no correlation was found between DAPK1 promoter methylation and other clinical parameters like age, BCR-ABL type and Thrombocytopenia. Conclusion: In summary we concluded that methylation status of DAPK1 gene is associated with advanced phase of CML and may be related to disease progression in chronic myeloid leukemia. Further study on a more number of patients is needed to explore the role of DAPK1 methylation in the prognosis of CML.",
keywords = "Chronic myeloid leukemia, DAPK1 Gene, Methylation, MSP-PCR technique",
author = "Rashid Mir and Imtiyaz Ahmad and Jamsheed Javid and Shazia Farooq and Prasant Yadav and Mariyam Zuberi and M. Masroor and Sameer Guru and Bhat, {Ajaz Ahmad} and {Ah Khatlani}, Tanveer and Naresh Gupta and Ray, {P. C.} and Alpana Saxena",
year = "2013",
month = "5",
day = "30",
doi = "10.4172/1948-5956.1000201",
language = "English",
volume = "5",
pages = "144--149",
journal = "Journal of Cancer Science and Therapy",
issn = "1948-5956",
publisher = "OMICS Publishing Group",
number = "4",

}

TY - JOUR

T1 - Epigenetic silencing of DAPK1 gene is associated with faster disease progression in India populations with chronic myeloid leukemia

AU - Mir, Rashid

AU - Ahmad, Imtiyaz

AU - Javid, Jamsheed

AU - Farooq, Shazia

AU - Yadav, Prasant

AU - Zuberi, Mariyam

AU - Masroor, M.

AU - Guru, Sameer

AU - Bhat, Ajaz Ahmad

AU - Ah Khatlani, Tanveer

AU - Gupta, Naresh

AU - Ray, P. C.

AU - Saxena, Alpana

PY - 2013/5/30

Y1 - 2013/5/30

N2 - Background: One of the major epigenetic changes in human cancer is DNA methylation of tumour suppressor genes which leads to silencing of gene leading to disease progression. Therefore, DNA methylation status of such genes may serve as the epigenetic biomarker for prognosis of human Chronic Myeloid Leukemia. Material and methods: We used MSP-PCR technique for the analysis of aberrant promoter DAPK1 methylation on 200 CML venous blood samples. Stastical analysis was done for evaluating differences between different parameters using SPSS 16.0 version. Results: We could detect 91/200 promoter methylation (45.5%) in CML patients. Percentage of methylation detected was seen higher in blast phase (63.07%) and in accelerated phase (48.1%) than in chronic phase (29.6%). A significant correlation was seen between CML stages and DAPK1 aberrant methylation. We also found a significant association of DAPK1 methylation in gender and in haematological resistance CML patients. However no correlation was found between DAPK1 promoter methylation and other clinical parameters like age, BCR-ABL type and Thrombocytopenia. Conclusion: In summary we concluded that methylation status of DAPK1 gene is associated with advanced phase of CML and may be related to disease progression in chronic myeloid leukemia. Further study on a more number of patients is needed to explore the role of DAPK1 methylation in the prognosis of CML.

AB - Background: One of the major epigenetic changes in human cancer is DNA methylation of tumour suppressor genes which leads to silencing of gene leading to disease progression. Therefore, DNA methylation status of such genes may serve as the epigenetic biomarker for prognosis of human Chronic Myeloid Leukemia. Material and methods: We used MSP-PCR technique for the analysis of aberrant promoter DAPK1 methylation on 200 CML venous blood samples. Stastical analysis was done for evaluating differences between different parameters using SPSS 16.0 version. Results: We could detect 91/200 promoter methylation (45.5%) in CML patients. Percentage of methylation detected was seen higher in blast phase (63.07%) and in accelerated phase (48.1%) than in chronic phase (29.6%). A significant correlation was seen between CML stages and DAPK1 aberrant methylation. We also found a significant association of DAPK1 methylation in gender and in haematological resistance CML patients. However no correlation was found between DAPK1 promoter methylation and other clinical parameters like age, BCR-ABL type and Thrombocytopenia. Conclusion: In summary we concluded that methylation status of DAPK1 gene is associated with advanced phase of CML and may be related to disease progression in chronic myeloid leukemia. Further study on a more number of patients is needed to explore the role of DAPK1 methylation in the prognosis of CML.

KW - Chronic myeloid leukemia

KW - DAPK1 Gene

KW - Methylation

KW - MSP-PCR technique

UR - http://www.scopus.com/inward/record.url?scp=84878185007&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878185007&partnerID=8YFLogxK

U2 - 10.4172/1948-5956.1000201

DO - 10.4172/1948-5956.1000201

M3 - Article

AN - SCOPUS:84878185007

VL - 5

SP - 144

EP - 149

JO - Journal of Cancer Science and Therapy

JF - Journal of Cancer Science and Therapy

SN - 1948-5956

IS - 4

ER -